BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
11/09/2020
Initial Lawsuit
01/12/2021
Lawsuit Progression
04/12/2021
Settlement
10/29/2021
Did GTT Communications mislead shareholders about adequate internal controls over financial reporting, including adjustments to its cost of telecommunication services?
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
11/09/2020
GTT explains delays in filings of quarterly report with ongoing examination of “the accounting for Cost of Telecommunications Services and [. . .] a number of issues in connection with the Company’s previously issued financial statements.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$3.96 | $3.75 | $0.21 | 5.6% |
A GTT shareholder filed a securities class action on behalf of all persons or entities that purchased or otherwise acquired GTT publicly traded securities from May 5, 2016 through November 9, 2020, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) the Company’s internal controls suffered from issues related to the recording and reporting of Cost of Telecommunications Services;
(ii) the Company’s previously reported Cost of Telecommunications was inaccurate or
accounted for unsupported adjustments;
(iii) inadequate internal controls would result in delays in the Company’s 10-Q quarterly reports;
(iv) as a result of the foregoing, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.
04/12/2021
The court issued an order appointing the lead plaintiff and lead counsel.
08/17/2021
Lead plaintiff brings this securities class action brought on behalf of all persons or entities that purchased or otherwise acquired GTT publicly traded securities from May 5, 2016 through July 30, 2021, both dates inclusive.
Operative complaint
On 10/29/2021, lead counsel The Rosen Law Firm, P.A. announced a proposed class action settlement.
The court preliminarily approved the settlement on 12/06/2021. The settlement has a total value of $2,000,000 in Cash.
The notice states that you may be included, if you purchased or otherwise acquired the company’s publicly traded common stock during the period from 05/05/2016 to 07/30/2021, inclusive.
According to the notice, the estimated average cash recovery per damaged share of common stock will be approximately $0.07 per share, before deduction of court-approved fees and expenses. Lead Counsel filed a motion for an award of attorneys’ fees not to exceed 30% of the $2,000,000 and payment of expenses not to exceed $65,000.
For information purposes only, last updated on 04/13/2022. Contact the claims administrator or lead counsel for further information.
On 03/21/2022, the court awarded lead counsel fees and reimbursement of expenses. The court awarded attorney fees of 30% of the total value of settlement (or $600,000) plus litigation expenses of $40,238.30. The lead plaintiff was awarded $7,500.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.